News Center

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

2020

2019

December 18, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia (CLL)

December 6, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis

October 23, 2019
AbbVie’s Suzanne Campbell recognized by peers

September 25, 2019
VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL), now reimbursed across Western Canada

July 25, 2019
AbbVie is committed to the elimination of hepatitis C in Canada by 2030

June 25, 2019
AbbVie Receives Positive Recommendation from the Institut national d’excellence en santé et en services sociaux (INESSS) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia

June 10, 2019
AbbVie’s MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

June 6, 2019
AbbVie Receives Positive Recommendation from the pan-Canadian Oncology Drug Review Expert Review Committee for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia

May 30, 2019
AbbVie’s MAVIRET™ now listed in New Brunswick

May 23, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for VENCLEXTA®, a treatment for chronic lymphocytic leukemia (CLL)

May 21, 2019
AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis

April 18, 2019
Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

April 11, 2019
AbbVie’s MAVIRET™ now reimbursed in Quebec

April 4, 2019
AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™

March 22, 2019
British Columbia PharmaCare Lists AbbVie’s Hepatitis C Treatment MAVIRET™ on its Formulary

February 21, 2019
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for its hepatitis C treatment MAVIRET™

February 20, 2019
AbbVie’s HUMIRA® (Adalimumab) approved by Health Canada to treat pediatric patients with chronic non-infectious anterior

2018

2017